Effect of captopril on serotonergic mechanisms in two-kidney, one-clip renal hypertensive rats. 1992

D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
Department of Pharmacodynamics, Medical Academy, Białystok, Poland.

In 2K,1C-RHR (two-kidney, one-clip hypertensive rats) serotonergic mechanisms in blood platelets were studied. The endogenous serotonin (5-HT) concentration in whole blood and in platelets remained unchanged in relation to the sham operated rats. Also the uptake of labelled 5-HT in rats with renal hypertension was not altered. However platelets aggregability was increased in 2K,1C-RHR. Acute administration of captopril (10 mg/kg and 100 mg/kg po) diminished blood pressure but did not change either the concentration of 5-HT in whole blood and in platelets of hypertensive rats or the uptake of this amine. Platelets aggregation and the amplifying effect of 5-HT in hypertensive rats were also unchanged after acute captopril administration. Similar results were observed after its administration in a dose of 30 mg/kg for one week. Our results indicate that captopril did not affect the platelets serotonergic mechanisms in 2K,1C-RHR.

UI MeSH Term Description Entries
D006978 Hypertension, Renovascular Hypertension due to RENAL ARTERY OBSTRUCTION or compression. Hypertension, Goldblatt,Goldblatt Syndrome,Goldblatt Hypertension,Renovascular Hypertension,Syndrome, Goldblatt
D008297 Male Males
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
January 1995, Polish journal of pharmacology,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
February 1983, Chest,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
January 1983, Clinical and experimental hypertension. Part A, Theory and practice,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
January 1993, Acta physiologica, pharmacologica et therapeutica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y [de] la Asociacion Latinoamericana de Farmacologia,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
August 1986, The American journal of physiology,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
January 1983, Pflugers Archiv : European journal of physiology,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
August 1997, European journal of pharmacology,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
August 1986, Neuroscience letters,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
January 1984, Clinical and experimental hypertension. Part A, Theory and practice,
D Morelowska, and E Chabielska, and D Pawlak, and A Azzadin, and A Białkowska, and D Krygicz, and W Buczko
September 1997, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!